Working... Menu

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin (ASTROH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02501434
Recruitment Status : Recruiting
First Posted : July 17, 2015
Last Update Posted : October 25, 2017
Information provided by (Responsible Party):
Robert F James, MD, FACS, FAANS, University of Louisville

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 2019
  Estimated Study Completion Date : December 2020
James RF, Shao EY, Page PS, Nazar RG, Martin LB, Dvorak J, Kanaan HK, Daniels MJ, Craycroft J, Rai SN, Everhart DE, Simard JM. Low-dose IV heparin preserves cognitive function in aneurysmal subarachnoid hemorrhage patients. [Unpublished Data]. Presented at AANS 82nd Annual Scientific Meeting. April 5-9, 2014. San Francisco, CA; Abstract #16572.